2024
National Myeloma Workshop
- Oral presentation:
- A Spencer, Myeloma and Related Diseases Registry (MRDR)
- Poster presentation:
- E. Moore et al., Supporting real world research in myeloma: the ‘data spine’ of the Australian and New Zealand Myeloma and Related Disease Registry
NZ Myeloma Summit
- Oral presentation:
- S Zhao et al., Real world comparison of treatment outcomes for myeloma in elderly transplant ineligible population with RVD, Rd and VCD in frontline setting: Results from MRDR Australia and New Zealand, on behalf of MRDR investigators
Blood 2024
- Annual Breakfast Meeting
- A Spencer, Real-world myeloma in ANZ and the Asia-Pacific: Registry progress and the latest MRDR data
- B Gration et al., The Impact of socioeconomic status on ASCT utilization and overall survival in myeloma in ANZ
- S Ringkowski et al., Metabolic syndrome in multiple myeloma: an analysis from the ANZ MRDR
- Oral Presentations:
- SL Lim et al., Functional High-Risk Multiple Myeloma (FHR-MM) following Lenalidomide-Bortezomib-dexamethasone (RVd) induction or bortezomib-cyclophosphamide-dexamethasone (VCD): An analysis from the Australian & New Zealand Myeloma and Related Diseases Registry (ANZ-MRDR).
- B Gration et al., Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis.
- E Moore et al., More efficient delivery of High-cost standard-of-care Therapies in Relapsed Multiple Myeloma using real-time feedback of Patient-reported outcome measures: the MY-PROMPT-2 trial
- A Irving et al., The EpiMAP Myeloma model: A new tool for predicting the impact of changes to the Multiple Myeloma treatment pathway
- S Ringkowski et al., Co-occurrence of Obesity and Diabetes adversely impacts overall survival (OS) in Multiple Myeloma (MM) – an analysis from the Australian and New Zealand Myeloma & Related Disease Registry (ANZ MRDR).
- B Gration et al., Impact of socioeconomic status on utilisation of ASCT and overall survival in multiple myeloma: a report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)
ASH 2024
Poster Presentation:
- K Lim et al., Assessing outcomes of MM patients with monoallelic and biallelic del(1p)
- G McCaughan., Impact of socioeconomic status on utilisation of ASCT and overall survival in multiple myeloma: a report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)
- G McCaughan., Management of biochemical relapse in myeloma patients - an Australian and New Zealand experience.
- K. Le., Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the FRAIL-M study
2023
ASH 2023
- Oral presentation:
- D. Wong et al., Cell free MYC DNA copy number identifies high-risk smoldering myeloma and newly diagnosed multiple myeloma.
- Poster presentations:
- K JC Lim et al., Impact of 1q21 gain and amplification on daratumumab-treated multiple myeloma: Real-world data from the Australia-new Zealand and asia-pacific myeloma registries
- A SO Tang et al., A prospective, multinational study of clinical and biological factors associated with short overall survival in multiple myeloma
Blood 2023
- Annual Breakfast Meeting:
- A. Spencer, Latest data and progress from the Australian & New Zeland MRDR.
- E. Moore, More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures.
- A. Irving, Epidemiological Modelling of Australian Patients with Myeloma (EpiMAP Myeloma).
- L. Oliver, Asia-Pacific Myeloma & Related Diseases Registry Progress and Results.
- Poster Presentations:
- E. Moore et al., More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient reported outcome measures.
- C Wellard et al., Factors associated with self-reported quality of life in a longitudinal study of patients with multiple myeloma (MM) in the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR).
- A. Irving et al., Modelling multiple myeloma using best clinical response to treatment to predict overall survival.
- K JC Lim et al., Inferior outcomes in t(11;14) multiple myeloma: a report from the Australian Lymphoma Leukaemia Group (ALLG) and the ANZ Myeloma and Related Diseases Registry (MRDR).
IMS 2023
- Poster Presentations:
- A. Irving et al., Modelling multiple myeloma using best clinical response to treatment to predict overall survival.
- E. Moore et al., More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient reported outcome measures.
2022
Australian Society for Medical Research, National Scientific Conference, Nov 2022, Sydney
- Oral Presentation:
- M Cantley et al., CTX-1 as a blood-based biomarker to identify risk of progression from smouldering myeloma to multiple myeloma.
National Myeloma Worshop, Oct 2022, Yarra Valley
- Oral Presentations:
- S Lim et al., MRDR and AMaRC trials update.
- K Bergin et al., Australian data from the Myeloma and Related Disease Registry.
- Poster Presentations:
- J Tan et al., Validation of the second revision of the international staging system in a real-world myeloma population: a myeloma and related diseases registry study.
- J Ng et al., Real world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the Australian and New Zealand, and Asia-Pacific Myeloma and related diseases registries.
Blood 2022, September, Sydney, Australia
- MRDR Annual Investigator and Interest Group breakfast meeting:
- A. Spencer, Myeloma in ANZ: MRDR progress and results
- T. Van Tonder, More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: introduction to the MY-PROMPT-2 trial
- J.Ng, Real-world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the ANZ, and the APAC MRDR)
- A. Spencer, Asia-Pacific MRDR: progress and results
- Oral Presentations:
- M. Cantley et al., CTX-1 levels can predict individuals at high risk of progression from smouldering myeloma to multiple myeloma
- S. Lim et al., Continuing poor outlook for relapsed Australian Multiple Myeloma (MM) patients: Impact of limited available therapies
- Poster Presentations:
- K. Chai et al., Infection patterns and outcomes in patients with newly diagnosed multiple myeloma: Preliminary results from the IMPROVE (Immunoglobulins in myeloma patients: research into outcomes, variation in practice and epidemiology) Cohort Study
- K. Chai et al., Variation in use of immunoglobulin and impact on survival in multiple myeloma: A report from the Australia/New Zealand MRDR and Asia-Pacific MRDR
- A. Irving et al., Epidemiological Modelling of Australian Patients with Myeloma, EpiMAP Myeloma
- J. Tan et al., Validation of the second revision of the International Staging System in a real-world myeloma population (R2-ISS): A Myeloma and Related Diseases Registry (MRDR) Study
- J. Ng. et al., Real-world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the Australian and New Zealand, and the Asia-Pacific Myeloma and Related Diseases Registries
International Myeloma Society Meeting 2022, August, Los Angeles, United States
- Poster Presentations:
- J. Ng. et al., Real world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the Australian and New Zealand, and Asia-Pacific Myeloma and related diseases registries.
- J. Tan et al., Validation of the second revision of the international staging system in a real-world myeloma population: a myeloma and related diseases registry study.
EHA Congress 2022, June, Vienna (hybrid)
- Poster presentations:
- K Chai et al., Variation in use of immunoglobulin and impact on survival in multiple myeloma: A report from the Australia/New Zealand MRDR and Asia-Pacific MRDR (e-Poster)
The European Society for Blood and Marrow Transplantation (EBMT) Meeting 2022, March, (Virtual)
- Poster Presentation:
- A. Tedjaseputra et al., Long-term follow-up of tandem autologous plus non-myeloablative allogeneic transplant in relapsed myeloma: An Australian report from the Alfred & the Myeloma and Related Diseases Registry (MRDR)
2021
ISOQOL 28th Annual Conference, October (virtual)
- Oral Presentation:
- E Moore: EQ-5D-5L utility scores at diagnosis and association with improved overall survival in Australian patients with multiple myeloma: Results from the Australian & New Zealand (ANZ) Myeloma and Related Diseases Registry (MRDR)
MRDR Annual Investigator and Interest Group Meeting (live webinar)
- Oral Presentations:
- Andrew Spencer, Real world myeloma in ANZ: registry progress and results
- P Joy Ho, Impact of biomarker (SLiM) inclusion to MM diagnostic criteria: diagnosis with SLiM alone versus end organ damage (CRAB) in the ANZ MRDR
- Khai Li Chai, Variation in use of Immunoglobulin in patients with myeloma
- Kate Vandyke, C-terminal telopeptide 1 (CTX-1) as a marker of high risk for progressing from smouldering to active myeloma
- Naomi Aoki, Asia-Pacific MRDR: progress and results
Blood 2021, (virtual conference)
- Oral Presentation
- PJ Ho, The impact of SLiM criteria in myeloma in a real-life population: patient & disease characteristics, treatment and outcome from the ANZ MRDR
- Poster Presentations
- A Tedjaseputra, Tandem autologous-allogeneic-SCT in relapsed multiple myeloma: a joint report from the Alfred and Myeloma and Related Diseases Registry (MRDR)
- R Cao, Causes of death in multiple myeloma in Australia: results from the Australian and New Zealand Myeloma and Related Diseases Registry (Narrated poster)
- E Moore, Higher EQ-5D-5L utility scores at diagnosis are associated with improved overall survival in Australian patients with multiple myeloma: Results from the Australian & New Zealand (ANZ) Myeloma and Related Diseases Registry (MRDR) (Narrated poster)
International Myeloma Workshop, September (hybrid conference, Vienna-based)
- Poster Presentations:
- PJ Ho, The impact of SLiM criteria in myeloma in a real-life population: clinical characteristics, treatment and outcome from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR) (Narrated poster)
- A Tedjaseputra, Tandem autologous + non-myeloablative allogeneic stem cell transplantation in relapsed multiple myeloma: an Australian joint report from the Alfred and Myeloma and Related Diseases Registry (MRDR)
Nursing Symposium, IMW
- Oral Presentation:
- E Moore, Higher EQ-5D-5L utility scores at diagnosis are associated with improved overall survival in Australian patients with multiple myeloma: Results from the Australian & New Zealand (ANZ) Myeloma and Related Diseases Registry (MRDR)
Using PROMs ‘Down-under’ – Supported by ISOQOL, July (virtual Sydney-based conference)
- Oral Presentation:
Monash SPHPM Registry Meeting
- Oral Presentation:
2020
ASH 2020 (virtual)
- Poster Presentation:
- Abstract:
MRDR Annual Interest Group Meeting (held by webinar, during the 3rd NMW, Australia 2020)
- A. Spencer, Myeloma in ANZ: MRDR progress and results
- C. Forsyth, Registry participation in a rural/regional setting
- D. Petrie, Epidemiological Modelling to deliver better care for Australians with MM
- K. Huynh, Asia Pacific MRDR: progress and results
- A. Spencer, AMARC: early phase clinical trials in multiple myeloma
3rd National Myeloma Workshop, Australia 2020 (virtual)
- Oral Presentation:
- A. Spencer, Early disease progression identifies an ultra-high risk sub-group of newly diagnosed multiple myeloma – A report from the MRDR
- Poster Presentation:
- J. Ho, The impact of SLiM criteria in myeloma in a real-life population: patient & disease characteristics, treatment and outcome from the ANZ MRDR
- R. Cao, Infection is a major contributor to causes of death in multiple myeloma: results from the ANZ MRDR
- N. Khajornjiraphan, Outcomes of bortezomib vs lenalidomide in patients with NDMM ineligible for ASCT – initial results from the ANZ MRDR
- A. Jackson, Outcome of patients with multiple cytogenetic abnormalities at diagnosis: Results from the ANZ MRDR
Monash SPHPM Registry Meeting 2020
- Oral Presentation:
- E. Moore/K Huynh, The Myeloma and Related Diseases Registry (MRDR) and the Asia Pacific arm of the MRDR (APAC MRDR) - an overview (invited)
Haematology Society of Taiwan Meeting 2020
- Oral Presentation:
- H. Quach, The Australian experience of patients with RRMM (MRDR data used) (invited)
European Haematology Association Congress 2020 (virtual)
- Poster Presentation:
2019
ASH, Orlando, USA, December
- Oral Presentations:
Blood, October, Perth, Australia
- Oral Presentations:
- A. Spencer et al. MRDR Interest Group breakfast meeting
- J. Zhao et al., Real-world treatment patterns in relapsed/refractory multiple myeloma in Australia: results from the Myeloma and Related Diseases Registry.
- E. Moore et al., Patient-reported outcome measures in multiple myeloma: real-time reporting to improve care (My-PROMPT) - a pilot randomised controlled trial.
- H. Blacklock et al., Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry.
International Myeloma Workshop 2019, September, Boston, USA
- Poster Presentations:
- H. Blacklock et al., Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
- P. Mollee et al., Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction
- E. Moore et al., Patient-reported outcome measures in multiple myeloma: real-time reporting to improve care (My-PROMPT) - a pilot randomised controlled trial
Alfred Week, June 2019
Myeloma UK Patient Registry Stakeholder Workshop, London, April
- E. Moore et al., Data with impact
2018
Inaugural Clinical Registries Summit, SPHPM, Monash, November
- A. Spencer. The Myeloma and Related Diseases Registry
- N. Aoki, E. Moore. The APAC MRDR and other MRDR International Collaborations
Blood, October, Brisbane
2nd National Myeloma Workshop, Yarra Valley, Australia, September
- Poster Presentations:
3rd Annual Educational Seminar, Myeloma Special Practice Network, HSANZ Nurses Group, Royal Adelaide Hospital: August
- A. Spencer. Real world outcomes from the Myeloma and Related Diseases Registry.
Registry Special Interest Group meeting, SPHPM, Monash: July
- E. Moore. News from the Myeloma and Related Diseases Registry.
Quality of Life Office meeting, University of Sydney, July
- E. Moore and T. King, Growth and outcomes of the Myeloma and Related Diseases Registry.
Alfred week, The Alfred Hospital, June
- Poster presentation:
EBMT, Lisbon, March
- Poster presentation:
2017
HAA, November, Sydney
- Oral presentations:
- A. Spencer et al., MRDR Interest Group meeting
- J. Ho, Renal impairment in myeloma: patient & disease characteristics, treatment, stem cell transplant & outcomes from the ANZ MRDR
- Poster Presentations:
European Haematology Association Congress, June
- Poster presentation:
Victorian Integrated Cancer Services Conference, Melbourne, May
- Oral presentation:
- A. Spencer, The myeloma and related diseases registry: a tool for practice improvement
Medical scientific advisory group (MSAG) meeting, Melbourne, May
- Oral presentation:
- A. Kalff, Myeloma Australia
International Myeloma Workshop, New Delhi, February
- Poster presentations:
Talks including reference to or introduction of the MRDR:
- H. Blacklock/T. King, National Haematology Nurses meeting, September 2017
2016
Australian Centre for Blood Diseases and Monash Health Research Symposium, Melbourne, November
HAA, Melbourne, November
- Oral presentations:
- A. Spencer et al., MRDR Interest Group meeting
- K. Bergin et al. Rates of Upfront Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma
- E. Moore et al. Renal impairment in myeloma: Characteristics and outcomes in patients with and without renal impairment in the ANZ Myeloma and Related Diseases Registry
National Myeloma Workshop, Yarra Valley, Vic, September 2016
- Oral presentation:
- Z. McQuilten, Putting the pieces together – Epidemiology Practice and Outcomes in Australia and New Zealand
- Poster presentations:
HSANZ Nurses Group, Myeloma Special Practice Network Education Seminar, August
- E. Moore, MRDR: Maturing data
Monash SPHPM Registry SIG, June
- E. Moore, MRDR: sustaining growth
ALLG Scientific Meeting, May
- A. Spencer, MRDR presentation to ALLG
Myeloma Awareness Day Meeting, Sydney, May
Talks including reference to or introduction of the MRDR:
- S. Gibbs, Myeloma lectures, Royal Darwin Hospital, Aug 2016
2015
Australian Centre for Blood Diseases and Monash Health Research Symposium, Melbourne, November
Korean Society of Hematology annual meeting, Seoul, November
HAA, Adelaide October
- Poster presentation:
MRDR Interest Group meeting
International Myeloma Workshop, Rome, September 2015
- Poster presentation:
Talks including reference to or introduction of the MRDR:
- A. Kalff, Binding site Educational Workshop, Melbourne, November, 2015
- A. Kalff, Myeloma Australia, Medical scientific advisory group (MSAG) meeting, Melbourne, November, 2015
- T. King, Update from IMW 2015 Rome: Nursing Symposium. HSANZ NG NSW Dinner Meeting. Sydney, November 2015 (Poster)
- T. King, Best practice in the administration of chemotherapy: Bortezomib focus. Tata Memorial Hspt Mumbai; Cancer Institute Chennai; Apollo Hospital Chennai; All India Institute of Medical Sciences (AIMS) Delhi; Rajiv Gandhi Cancer Institute Delhi India, August, 2015
- A. Kalff, Myeloma Australia, medical scientific advisory group (MSAG) meeting, Melbourne, May, 2015
2014
Myeloma Scientific Advisory Group, Myeloma Foundation Australia, Melbourne, Victoria
MRDR Interest Group Meeting, HAA, Perth, Western Australia, October
Talks including reference to or introduction of the MRDR:
- T. King, The Clinical Care of Multiple Myeloma Patients with Targeted Therapy. Taipei, Taiwan, November 2014
- T. King, The Clinical Care of Multiple Myeloma Patients with Targeted Therapy. Kaohsiung, Taiwan, November 2014
- T. King, Making sense of myeloma: An overview of treatment. Leukaemia and Blood Cancer Foundation & HSANZ Nurses Group Educational meeting for nurses, September 2014
- T. King, Myeloma: An overview of disease, treatments and management of side effects. Leukaemia and Blood Cancer Foundation Patient and Family Forum Auckland New Zealand, September 2014
- T. King, The Clinical Care of Multiple Myeloma Patients. The First Affiliated Hospital of College of Medicine Zhejiiang University. Hangzhou, China, February 2014
- T. King, The Clinical Care of Multiple Myeloma Patients. Shanghai Changzheng, Shanghaim, China, February 2014
- T. King, The Clinical Care of Multiple Myeloma Patients. Institute of Haematology and Blood Diseases Hospital Chinese Academy of Medical Sciences. Tianjin, China, February 2014
2013
HAA Investigator Meeting, Gold Coast, Queensland
